Zevra Therapeutics (ZVRA) Operating Leases (2019 - 2026)

Zevra Therapeutics (ZVRA) has 8 years of Operating Leases data on file, last reported at $1.1 million in Q1 2026.

• Quarterly Operating Leases fell 0.95% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 0.95% YoY) and the FY2025 annual result came in at $859000.0, up 8.46% from the prior year.
• Operating Leases rose to $1.1 million in Q1 2026, from $859000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.6 million in Q2 2025 to a low of $456000.0 in Q4 2023.
• A 5-year average of $941153.8 and a median of $859000.0 in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases plunged 46.91% — and 2025, when it surged 191.3%.
• Tracing ZVRA's Operating Leases over 5 years: stood at $843000.0 in 2022, then slumped by 45.91% to $456000.0 in 2023, then surged by 73.68% to $792000.0 in 2024, then gained by 8.46% to $859000.0 in 2025, then jumped by 33.53% to $1.1 million in 2026.
• The last three Operating Leases figures came in at $1.1 million (Q1 2026), $859000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.